DME Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

DME Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.8M	Sell	2,886,059 -24,670	-0.8%	-$822K	2.5%	12
2026 Q1	$87.7M	Sell	2,910,729 -148,005	-5%	-$4.76M	2.75%	13
2025 Q4	$95.5M	Sell	3,058,734 -720,043	-19%	-$17.7M	3.35%	10
2025 Q3	$76.3M	Hold	3,778,777	–	–	3%	10
2025 Q2	$63.3M	Buy	3,778,777 +3,210,577	+565%	+$51.8M	2.72%	12
2025 Q1	$8.73M	Buy	568,200 +99,650	+21%	+$1.78M	0.44%	23
2024 Q4	$10.3M	Buy	468,550 +143,700	+44%	+$2.61M	0.53%	22
2024 Q3	$5.85M	Hold	324,850	–	–	0.24%	28
2024 Q2	$5.28M	Hold	324,850	–	–	0.26%	27
2024 Q1	$4.58M	Buy	+324,850	New	+$4.09M	0.21%	29

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

DME Capital Management's TEVA Position: Q2 2026 in Review

DME Capital Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 0.85% in Q2 2026, selling an estimated $822K and leaving 2,886,059 shares worth $97.8M. The position accounts for 2.5% of the portfolio, ranked #12.

DME Capital Management first reported a position in TEVA in Q1 2024 and has held it in 10 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

DME Capital Management held 2,886,059 shares of Teva Pharmaceutical Industries Limited worth $97.8M as of Q2 2026.
DME Capital Management sold 24,670 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $822K.
Teva Pharmaceutical Industries Limited made up 2.5% of DME Capital Management's portfolio in Q2 2026, its #12 holding.
DME Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q1 2024 and has held it in 10 quarters since.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on DME Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.